CClinicalTrials.gg
Not yet recruitingNCT07699627INCREDIBLEUpdated Jul 13, 2026

INCREmental DIalysis and Diet for a Better Life Experience

A Phase 2 interventional study of Supplementation by ketosteril in Incremental Haemodialysis, sponsored by Centre Hospitalier le Mans. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by Centre Hospitalier le Mans · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Previous studies suggest that the supplementation of essential amino acids and ketaoacids may prolong the duration of the incremental phase of peritoneal dialysis. There is no data on incremental haemodialysis patients. Such data would be highly needed to support the management of haemodialysis patients in the transition phase from "pre-dialysis" to "full dose" dialysis. In this context, investigator proposed a randomized "add on" trial, to evaluate the effect of the addition of Ketosteril to the usual nutritional plan to patients who start haemodialysis in incremental way.

02

Conditions studied

  • Incremental Haemodialysis

Keywords

  • ketosteril
  • incremental haemodialysis
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Adult patients (aged 18 years or older)
  • Able and accepting to give informed consent
  • Starting iHD in the Centre Hospitalier Le Mans

Exclusion criteria

Exclusion Criteria:

  • Denying informed consent
  • Acute kidney injury (AKI)
  • Life expectancy of less than 3 months, or kidney transplantation scheduled within 3 months
  • Cognitive impairment severe enough to limit understanding and acceptance of the study
  • Impossibility to regain kidney function (bilateral nephrectomy, documented irreversible complete destruction of the kidney tissue)
  • Patient with genetic disease affecting amino acid metabolism
  • Hypercalcemia defined as calcemia beyond the upper limit of normality according to the laboratory where the test is performed and persisting for at least one month
  • Hypersensitivity to the active substances or to any of the excipients of Ketosteril
  • Non-compliance to dialysis prescription
  • Previous enrolment in a randomized study using Ketosteril
  • Currently enrolled in another interventional clinical trial
  • Protected by law (patient under guardianship, minor, prisoner, pregnant or breastfeeding woman, …)
04

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • No intervention
    Control arm

    Current dietary management, without Ketosteril

  • Experimental
    Interventional arm

    Current dietary management with supplementation by Ketosteril

    Drug: Supplementation by ketosteril

Interventions

  • DrugSupplementation by ketosteril

    1 tablet each 10 kg of ideal Body Weight is dispensed per day

05

What researchers measure

Primary outcomes

  1. Duration of incremental haemodialysis period

    Duration in months of the incremental haemodialysis period (defined as less than 3 times per week but excluding the cases in which dialysis frequency is reduced in the context of palliative and end-of life care)

    Time frame: 24 months

Secondary outcomes

  1. Mortality

    Number of patients who have died (patients who discontinue dialysis in the context of an "end of life care project" are considered as deceased at the start of the program of palliative care)

    Time frame: 24 months

  2. Hospitalization rates

    Hospitalization rates (all causes), excluding the hospitalization at dialysis start and hospitalization for end-of-life care.

    Time frame: 24 months

  3. Combined outcome mortality and hospitalization

    Time frame: 24 months

  4. Quality of life

    Quality of life is assessed by questionnaire WHO QoL (from 26 to 130, the higher the score, the better the quality of life)

    Time frame: 24 months

  5. Nutritional status

    Nutritional status will be assessed by evaluation of body composition by Bioelectrical Impedance Analysis (BIA).

    Time frame: 24 months

  6. Costs

    Costs related to incremental Haemodialysis and Ketosteril, with respect to costs of standard Haemodialysis

    Time frame: 24 months

  7. Water saving

    Savings in terms of water (m\^3) will be calculated based on the number of spared hemodialysis sessions compared to a standard schedule three times/week hemodialysis

    Time frame: 24 months

  8. Perceived diet quality

    Perceived diet quality is assessed by questionnaire MDRD (Modification of Diet in Renal Disease, the higher the score, the more satisfied the patient is with their diet)

    Time frame: 24 months

  9. Energy savings

    Savings in terms of energy (kW/h) will be calculated based on the number of spared hemodialysis sessions compared to a standard schedule three times/week hemodialysis

    Time frame: 24 months

  10. Waste Management

    Savings in terms of waste (kg) will be calculated based on the number of spared hemodialysis sessions compared to a standard schedule three times/week hemodialysis

    Time frame: 24 months

  11. Assessment of Appetite

    Appetite is assessed by council on nutrition appetite questionnaire (A CNAQ score of 28 or less indicates a significant risk of weight loss of at least 5% within six months)

    Time frame: 24 months

06

Study locations

1 site
  • Centre Hospitalier Le Mans
    Le Mans, 72000, France
    • Christelle JADEAU, MD · Contact · cjadeau@ch-lemans.fr · 02 44 71 07 81
    • Massimo TORREGGIANI, MD · Principal investigator
07

Registry details

Key details

Study ID
NCT07699627
Lead sponsor
Centre Hospitalier le Mans
Responsible party
Sponsor
First posted
Jul 13, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Sep 1, 2030 (estimated)
Completion
Sep 1, 2030 (estimated)
Last update
Jul 13, 2026

Study contacts

Christelle JADEAU, MD
Contact
cjadeau@ch-lemans.fr
0244710781 ext. +33
Massimo TORREGGIANI, MD
Contact
mtorreggiani@ch-lemans.fr
02 53 04 04 70 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion